CRP and cancer: Inflammation-based scoring systems, including the Glasgow Prognostic Score (GPS) determined by serum levels of CRP, NLR and PLR, are novel predictors of outcome in cancer patients, and have been extensively used in a variety of clinical scenarios, such as operable patients, chemo/radiotherapy, and inoperable patients [44,46,47].